Trial: Keynote-716

KEYNOTE-716: safety profile and results of pembrolizumab for melanoma

KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma

KEYNOTE-716: adjuvant therapy with pembrolizumab for patients with high-risk stage II melanoma

KEYNOTE-716: adjuvant pembrolizumab for high-risk melanoma

KEYNOTE-716: Longer follow up supports pembrolizumab use in stage IIB/IIC melanoma

Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanoma

Final analysis of distant metastasis-free survival in the KEYNOTE-716 study

#ESMO21 Highlights on pembrolizumab in fully resected high-risk stage II melanoma: KEYNOTE-716 study

European Society for Medical Oncology (ESMO)

KEYNOTE-716: pembrolizumab in stage 2B/2C cutaneous melanoma

Results from the KEYNOTE-716: Pembrolizumab versus placebo after complete resection of high-risk...

Melanoma | 2022 OneOncology Conference

Total Health | Oncology

Expert Report on novel data in (neo)adjuvant treatment of melanoma from ASCO 2022

European Society for Medical Oncology (ESMO)

Adjuvant therapy for high-risk melanoma

VÑ KEYNOTE-716, Melanoma, ady [Pembrolizumab vs Placebo]

Galo A Sánchez

Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma

Society for Melanoma Research 2022: Adjuvant and TIL Therapy

Melanoma highlights from ESMO 2021

Evolution of melanoma therapies from advanced to (neo)adjuvant (Alexander Eggermont)

НМИЦ онкологии им. Н.Н. Петрова

Melanoma highlights from ESMO 2021

How to Understand the Standard of Care for Stage II Melanoma Patients

From The Clinic To The Living Room: Melanoma 101